Latest Breaking News On - Mikhail kalinichev - Page 1 : vimarsana.com

Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024

Geneva, Switzerland, May 31, 2024 - Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological.

United statesMikhail kalinichevTim dyerMike sinclairSwiss exchangeJanssen pharmaceuticals incTranslational scienceAddex therapeuticsConference callParticipant dial inAmerican depositary sharesForward looking statementsPrivate securities litigation reform actAddex therapeutic annual reportAddex therapeutic

Addex Therapeutics to Release Q1 2024 Financial Results and

Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio.

United statesMikhail kalinichevMike sinclairTim dyerSwiss exchangeJanssen pharmaceuticals incTranslational scienceAddex therapeuticsConference callParticipant dial inAmerican depositary shares

Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024

Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesTim dyerMike sinclairMikhail kalinichevSwiss exchangeJanssen pharmaceuticals incRelease full yearHost conference callAddex therapeuticsTranslational scienceConference callParticipant dial inJanssen pharmaceuticalsAmerican depositary sharesExecutive officerHalsin partners

Addex and Perceptive Launch Neurosterix with $63 Million to

Addex receives CHF5M and 20% share of Neurosterix Perceptive Advisors leads $63M investment into Neurosterix Addex contributes portfolio of.

New yorkUnited statesMikhail kalinichevTim dyerFred calloriRobert lutjensJean philippe rocherMike sinclairAddex neurosterixSwiss exchangePerceptive life sciences fundPerceptive xontogeny venture fundJanssen pharmaceuticals incHoc announcement pursuantPerceptive advisorsAcorn bioventures

Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders

Addex receives CHF5M and 20% share of Neurosterix Perceptive Advisors leads $63M investment into Neurosterix Addex contributes portfolio of preclinical neuroscience assets and.

United statesNew yorkAddex neurosterixFred calloriJean philippe rocherMike sinclairRobert lutjensTim dyerMikhail kalinichevPerceptive life sciences fundJanssen pharmaceuticals incSwiss exchangePerceptive xontogeny venture fundHoc announcement pursuantPerceptive advisorsAcorn bioventures